Glioma Response to IDH Inhibition: Real-World Experience

Rimas V. Lukas; Craig Horbinski

doi:10.1158/1078-0432.CCR-23-2164

Glioma Response to IDH Inhibition: Real-World Experience

Rimas V. Lukas^*, Craig Horbinski

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Treatment of IDH-mutated non-enhancing grade 2 and 3 diffuse gliomas with ivosidenib leads to reduction of tumor size when assessed via volumetric MRI. Isocitrate dehydrogenase inhibition has a therapeutic benefit in patients with these tumors.

Original language	English (US)
Pages (from-to)	4709-4710
Number of pages	2
Journal	Clinical Cancer Research
Volume	29
Issue number	23
DOIs	https://doi.org/10.1158/1078-0432.CCR-23-2164
State	Published - 2023

Funding

R.V. Lukas and C. Horbinski are supported by the NIH (P50CA221747).

ASJC Scopus subject areas

General Medicine

Access to Document

10.1158/1078-0432.CCR-23-2164

Cite this

@article{d85ca6bceecd44d2b3b614a2472eb520,

title = "Glioma Response to IDH Inhibition: Real-World Experience",

abstract = "Treatment of IDH-mutated non-enhancing grade 2 and 3 diffuse gliomas with ivosidenib leads to reduction of tumor size when assessed via volumetric MRI. Isocitrate dehydrogenase inhibition has a therapeutic benefit in patients with these tumors.",

author = "Lukas, {Rimas V.} and Craig Horbinski",

note = "Publisher Copyright: {\textcopyright}2023 American Association for Cancer Research.",

year = "2023",

doi = "10.1158/1078-0432.CCR-23-2164",

language = "English (US)",

volume = "29",

pages = "4709--4710",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "23",

}

TY - JOUR

T1 - Glioma Response to IDH Inhibition

T2 - Real-World Experience

AU - Lukas, Rimas V.

AU - Horbinski, Craig

PY - 2023

Y1 - 2023

N2 - Treatment of IDH-mutated non-enhancing grade 2 and 3 diffuse gliomas with ivosidenib leads to reduction of tumor size when assessed via volumetric MRI. Isocitrate dehydrogenase inhibition has a therapeutic benefit in patients with these tumors.

AB - Treatment of IDH-mutated non-enhancing grade 2 and 3 diffuse gliomas with ivosidenib leads to reduction of tumor size when assessed via volumetric MRI. Isocitrate dehydrogenase inhibition has a therapeutic benefit in patients with these tumors.

UR - http://www.scopus.com/inward/record.url?scp=85178650352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85178650352&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-23-2164

DO - 10.1158/1078-0432.CCR-23-2164

M3 - Article

C2 - 37738033

AN - SCOPUS:85178650352

SN - 1078-0432

VL - 29

SP - 4709

EP - 4710

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 23

ER -

Glioma Response to IDH Inhibition: Real-World Experience

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this